CPT codes

53947 CPT codes with hospital pricing data in the network.

• CPT 506T — MAC PGMT OPT DNS MEAS HFP (82 hospitals, — samples)
• CPT 506U — Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus (85 hospitals, — samples)
• CPT 507T — NEAR IFR 2IMG MIBMN GLND I&R (85 hospitals, — samples)
• CPT 507U — Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected (85 hospitals, — samples)
• CPT 508T — Ultrasound Measurement Of Bone Density In Shin Bone (9 hospitals, — samples)
• CPT 508U — Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection (85 hospitals, — samples)
• CPT 509T — PATTERN ERG W/I&R (82 hospitals, — samples)
• CPT 509U — Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection (85 hospitals, — samples)
• CPT 50U — TRGT GEN SEQ DNA 194 GENES (85 hospitals, — samples)
• CPT 510T — RMVL SINUS TARSI IMPLANT (85 hospitals, — samples)
• CPT 510U — Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype (85 hospitals, — samples)
• CPT 511T — RMVL&RINSJ SINUS TARSI IMPLT (85 hospitals, — samples)
• CPT 511U — Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug (85 hospitals, — samples)
• CPT 512T — ESW INTEG WND HLG 1ST WND (85 hospitals, — samples)
• CPT 512U — Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of M (85 hospitals, — samples)
• CPT 513T — ESW INTEG WND HLG EA ADDL (85 hospitals, — samples)
• CPT 513U — Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, repor (85 hospitals, — samples)
• CPT 514T — Visual Axis Identification Using Patient Fixation During Operation (7 hospitals, — samples)
• CPT 514U — Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) (85 hospitals, — samples)
• CPT 515T — INSJ WCS LV COMPL SYS (85 hospitals, — samples)
• CPT 515U — Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) (85 hospitals, — samples)
• CPT 516T — INSJ WCS LV ELTRD ONLY (85 hospitals, — samples)
• CPT 516U — Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status (85 hospitals, — samples)
• CPT 517T — INSJ WCS LV BOTH COMPNT PG (85 hospitals, — samples)
• CPT 517U — Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications (85 hospitals, — samples)
• CPT 518T — RMVL PG WCS LV BATTERY ONLY (85 hospitals, — samples)
• CPT 518U — Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications (85 hospitals, — samples)
• CPT 519T — RMV&RPLCMT PG WCS LV BOTH (85 hospitals, — samples)
• CPT 519U — Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LC-MS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medication (85 hospitals, — samples)
• CPT 51U — RX MNTR LC-MS/MS UR/BLD 31 (85 hospitals, — samples)
• CPT 520T — RMV&RPLCMT PG WCS LV BATTERY (85 hospitals, — samples)
• CPT 520U — Therapeutic drug monitoring, 200 or more drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications (85 hospitals, — samples)
• CPT 521T — INTERROG DEV EVAL WCS IP (85 hospitals, — samples)
• CPT 521U — Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood (85 hospitals, — samples)
• CPT 522T — PRGRMG DEV EVAL WCS IP (85 hospitals, — samples)
• CPT 522U — Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiqualitative, blood (85 hospitals, — samples)
• CPT 523U — Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location (85 hospitals, — samples)
• CPT 524 — ANESTH CHEST DRAINAGE (91 hospitals, — samples)
• CPT 524T — EV CATH DIR CHEM ABLTJ W/IMG (85 hospitals, — samples)
• CPT 524U — OB PE SFLT-1/PLGF IA SRM/PLS (89 hospitals, — samples)
• CPT 525T — INSJ/RPLCMT COMPL IIMS (85 hospitals, — samples)
• CPT 525U — Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug (85 hospitals, — samples)
• CPT 526T — INSJ/RPLCMT IIMS ELTRD ONLY (85 hospitals, — samples)
• CPT 526U — Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time (85 hospitals, — samples)
• CPT 527T — INSJ/RPLCMT IIMS IMPLT MNTR (85 hospitals, — samples)
• CPT 527U — Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected (85 hospitals, — samples)
• CPT 528T — PRGRMG DEV EVAL IIMS IP (85 hospitals, — samples)
• CPT 528U — Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquanti (86 hospitals, — samples)
• CPT 529T — INTERROG DEV EVAL IIMS IP (85 hospitals, — samples)
• CPT 529U — Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE (85 hospitals, — samples)